Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 506 matching drugs for FGFR2 — including drugs targeting any of its 24 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR2 Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR2 Direct 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR2 Direct 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR2 Direct 3
pembrolizumab, belzutifan, lenvatinib FGFR2 Direct 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR2 Direct 2
bbi-355, erlotinib, futibatinib FGFR2 Direct 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FGFR2 Direct 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR2 Direct 2
lenvatinib, pembrolizumab FGFR2 Direct 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR2 Direct 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR2 Direct 2
nintedanib FGFR2 Direct yes 2
nintedanib, pembrolizumab FGFR2 Direct 2
pembrolizumab, lenvatinib FGFR2 Direct 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR2 Direct 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR2 Direct 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR2 Direct 2
regorafenib FGFR2 Direct yes 2
regorafenib, laboratory biomarker analysis FGFR2 Direct 2
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging FGFR2 Direct 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography FGFR2 Direct 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FGFR2 Direct 1
erdafitinib FGFR2 Direct yes 1
h101, tislelizumab, lenvatinib FGFR2 Direct 1
lenvatinib, bevacizumab FGFR2 Direct 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) FGFR2 Direct 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel FGFR2 Direct 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel FGFR2 Direct 1
pemigatinib FGFR2 Direct yes 1
ponatinib FGFR2 Direct 1
regorafenib, lomustine FGFR2 Direct 1
regorafenib, nivolumab, capeox, folfox regimen FGFR2 Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FGFR2 Direct 1
regorafenib, temozolomide FGFR2 Direct 1
selpercatinib FGFR2 Direct 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome FGFR2 Direct 1
tace, lenvatinib, combined with tislelizumab group FGFR2 Direct 1
tace, tislelizumab, lenvatinib FGFR2 Direct 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 FGFR2 Direct 1
nintedanib esylate FGFR2 Direct yes 0
palifermin FGFR2 Direct yes 0
pazopanib FGFR2 Direct yes 0
pazopanib hydrochloride FGFR2 Direct yes 0
vandetanib FGFR2 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
binimetinib and encorafenib BRAF SSL via BRAF yes 1
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
osimertinib EGFR SSL via EGFR yes 1
sunitinib FLT4 SSL via FLT4 yes 5
docetaxel, thalidomide BCL2 SSL via BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BCL2 SSL via BCL2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FLT4 SSL via FLT4 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FLT4 SSL via FLT4 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR4 SSL via FGFR4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
afatinib ERBB2 SSL via ERBB2 yes 3
amg 193, docetaxel, comparator amg 193 test tablet BCL2 SSL via BCL2 3
bms-986340, bms-936558-01, docetaxel BCL2 SSL via BCL2 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR4 SSL via FGFR4 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
pembrolizumab, belzutifan, lenvatinib FGFR4 SSL via FGFR4 3
pembrolizumab, belzutifan, lenvatinib FLT4 SSL via FLT4 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel BCL2 SSL via BCL2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FLT4 SSL via FLT4 2
alvocidib, paclitaxel BCL2 SSL via BCL2 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BCL2 SSL via BCL2 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 FLT4 SSL via FLT4 2
bbi-355, erlotinib, futibatinib FGFR4 SSL via FGFR4 2
bryostatin 1, paclitaxel BCL2 SSL via BCL2 2
btla inhibitor (js004), toripalimab, paclitaxel, cisplatin BCL2 SSL via BCL2 2
capecitabine, docetaxel BCL2 SSL via BCL2 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy BCL2 SSL via BCL2 2
carboplatin, docetaxel BCL2 SSL via BCL2 2
carboplatin, endoscopic biopsy, external beam radiation therapy, lenvatinib mesylate, paclitaxel, pembrolizumab, resection BCL2 SSL via BCL2 2
carboplatin, esophagectomy, intensity-modulated radiation therapy, paclitaxel, proton beam radiation therapy, quality-of-life assessment, questionnaire administration, folfox regimen, capox regimen, docetaxel, 5fu BCL2 SSL via BCL2 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy BCL2 SSL via BCL2 2
carboplatin, paclitaxel, panitumumab, radiotherapy BCL2 SSL via BCL2 2
carboplatin, paclitaxel, radiation therapy, telomerase-specific type 5 adenovirus obp-301 BCL2 SSL via BCL2 2
carboplatin, paclitaxel, three-dimensional conformal radiation therapy BCL2 SSL via BCL2 2
cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy BCL2 SSL via BCL2 2
chemotherapy, cisplatin, paclitaxel, low-let electron therapy, low-let photon therapy BCL2 SSL via BCL2 2
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy BCL2 SSL via BCL2 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy BCL2 SSL via BCL2 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy BCL2 SSL via BCL2 2
cisplatin, paclitaxel, surgical procedure, radiation therapy BCL2 SSL via BCL2 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study BCL2 SSL via BCL2 2
dkn-01 150 mg, paclitaxel, pembrolizumab, dkn-01 300 mg BCL2 SSL via BCL2 2
docetaxel, 5-fu, radiotherapy, esophagectomy, dexamethasone BCL2 SSL via BCL2 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.